

Aubagne, France, March 26, 2024

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

At today's combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders have granted discharge to all directors by a large majority and approved the renewal of the appointments as Directors of Susan Dexter and Anne-Marie Graffin for a three-year term of office.

From March 26, 2024, onwards, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg, Chairman; René Fáber, CEO; Pascale Boissel; Susan Dexter; Romaine Fernandes; Anne-Marie Graffin; Lothar Kappich; and Henri Riey.

Sartorius Stedim Biotech shareholders approve dividend proposal

Furthermore, the shareholders approved all resolutions by a large majority, including the proposal to pay a dividend of 0.69 euros per share for fiscal 2023. The total profit distributed will be 67.1 million euros. The dividend will be paid on April 4, 2024.

This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The French press release is the legally binding version.

Press Images

<https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/board>

Financial calendar

April 18, 2024	Publication of the quarterly figures January to March 2024
July 19, 2024	Publication of the half-year figures January to June 2024
October 17, 2024	Publication of the nine-month figures January to September 2024

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In

2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe.

Contact

Timo Lindemann

External Communications

+49 (0)551.308.4724

timo.lindemann@sartorius.com

Follow Sartorius Stedim Biotech on [LinkedIn](#).